This weed stock is undervalued, analyst says
The analyst expects Trulieve to generate Adjusted EBITDA of US$401.1-million on revenue of US$1.178-billion in fiscal 2026, improving to US$415.8-million on revenue of US$1.221-billion in fiscal 2027.
Here’s why Tilray Brands stock has crashed after cannabis reclassification
Tilray Brands stock price crashed to its lowest level since August last year despite the recent US policy change that opened the door to its expansion in the country. TLRY dropped to $5.6, much lower …
Is Tilray the Best Value Play in the $7.4 Billion Cannabis Beverage Market?
Although cannabis stocks have not performed well over the past five years, there is still some hope left for the industry. According to some projections, the market will continue …
Why Tilray’s Marijuana Rescheduling Sizzle Has Fizzled
Rescheduling does matter greatly. Moving from Schedule I to Schedule III takes marijuana out of the same league as heroin, and places it in the same ca …
Cannabis ETFs: Regulatory Momentum Returns Focus
Cannabis stocks often trade less on traditional fundamentals alone and more on changes in policy. Cannabis ETFs are a narrow but differentiated thematic play on potential regulatory upside.
CBD Stocks Creating Opportunities – Established (BCCI), (STG), (WEED), (ACRGF), (RLTR), (CBMJ), and Newcomer (VAPR) Lead the Charge
You would have to be living in isolation to have not picked up on the hottest marijuana derivative consumable and therapeutic center isolate CBD. CBD “Cannabidiol” is the non-psychoactive full spectrum derivative of the hemp and marijuana plant largely credited for the majority of the medical beneficial attributes associated with marijuana.
‘Devastating’: Retired firefighter says he lost most of his retirement savings investing in stocks that were targeted by a famous short-seller
He turned $110K into $190K, then watched his savings vanish after public criticism from from Citron Research’s Andrew Left.
Retired firefighter says he lost most of his savings investing in stocks that were targeted by famous short-seller
He turned $110K into $190K, then watched his savings vanish after public criticism from from Citron Research’s Andrew Left.
Canopy Growth’s Stock Just Dropped — Here’s Why I’m Still Not Buying
For anyone who has observed Canopy Growth (NASDAQ: CGC) during the past few years, it won’t be shocking to learn that the marijuana company’s stock is diving in May. Since the start of the month, it’s …
Auxly Cannabis is still undervalued, this analyst says
Haywood analyst Neal Gilmer maintained a “Buy” rating and $0.25 target on Auxly Cannabis Group (Auxly Cannabis Group Stock Quote, Chart, News, Analysts, Financials TSX:XLY) in a May 14 report after …
Cannabis Stocks Soared—Than Sank. Here’s What Investors Need to Know.
Cannabis stocks and funds that hold them surged after the Trump administration moved it from the government most restrictive drug category to one that can be obtainable with a prescription.
Cannabis Stocks Jump After U.S. Reclassifies Marijuana as Less Dangerous Drug
Shares of cannabis companies rose after the Trump administration reclassified marijuana as a less dangerous drug. Curaleaf increased 5.8% in premarket trading after surging 26% Wednesday on a report …
Tilray and other pot stocks soar as Trump is reportedly ready to reclassify cannabis
The move, which could open up medical research on cannabis as well as banking services for growers, follows an executive order to reclassify the substance in December.
Tilray Brands (TLRY) Price Forecast: Cannabis Rescheduling Fuels Recovery
Trend Identification & Analysis: How to Read the Market’s Footprints Before the Crowd Does Cannabis-related stocks and ETFs have been among the worst-performing groups in recent years. A peak was …
MSOS: Trump’s Green Light – Why Cannabis Stocks Are Surging On Rescheduling News (Rating Upgrade)
MSOS is upgraded to Buy ahead of US cannabis rescheduling catalysts—Schedule III could end 280E taxes, boost MSO profits, and drive re-ratings. Read more here.
Recent Comments